CHATTEM NON-CRP PAMPRIN SKUs CONSTITUTE MORE THAN 75% OF BRAND SALES
This article was originally published in The Tan Sheet
CHATTEM NON-CRP PAMPRIN SKUs CONSTITUTE MORE THAN 75% OF BRAND SALES in 1993, according to sales data in Consumer Product Safety Commission documents supporting the commission's case against the company. CPSC said that the package sizes of Maximum Strength Pamprin Tablets, Maximum Strength Pamprin Caplets, and Pain Relief Pamprin Caplets that do not include child-resistant packaging features account for 86%, 75.7%, and 89.6%, respectively, of each Pamprin product's 1993 sales.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC